Baxter turned it around last, year, with a more than 8% addition to the top line and a bottom-line surge of some 57%. “2011 was a very successful year for Baxter as we continue to fulfill our mission of providing innovative life-saving and life-sustaining therapies that advance patient care worldwide,” chairman & CEO Robert Parkinson Jr. said at the time. But all’s not peaches and cream in Deerfield; the U.S. Securities & Exchange Commission subpoenaed Baxter this spring for documents on the recall of its Colleague and Syndeo infusion pumps.
Home » Baxter International